|
1
|
Tarlan B and Kiratli H: Uveal melanoma:
Current trends in diagnosis and management. Turk J Ophthalmol.
46:123–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R
and Fan X: Uveal melanoma: Progress in molecular biology and
therapeutics. Ther Adv Med Oncol.
12(1758835920965852)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xu Y, Lou L, Wang Y, Miao Q, Jin K, Chen M
and Ye J: Epidemiological Study of Uveal Melanoma from US
Surveillance, Epidemiology, and End Results Program (2010-2015). J
Ophthalmol. 2020(3614039)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Collaborative Ocular Melanoma Study Group.
Histopathologic characteristics of uveal melanomas in eyes
enucleated from the collaborative ocular melanoma study. COMS
report No 6. Am J Ophthalmol. 125:745–766. 1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Aronow ME, Topham AK and Singh AD: Uveal
melanoma: 5-Year update on incidence, treatment, and survival (SEER
1973-2013). Ocul Oncol Pathol. 4:145–151. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
American Cancer Society. Ocular melanoma.
Collaborative Ocular Melanoma Study (COMS) staging of melanoma of
the eye, 2018. Available online: https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/staging.html.
|
|
8
|
Egan KM, Ryan LM and Gragoudas ES:
Survival implications of enucleation after definitive radiotherapy
for choroidal melanoma: An example of regression on time-dependent
covariates. Arch Ophthalmol. 116:366–370. 1998.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Malouff TD and Trifiletti DM (eds):
Principles and practice of particle therapy. Wiley.
(pp204)2022.
|
|
10
|
Collaborative Ocular Melanoma Study Group.
The COMS randomized trial of iodine 125 brachytherapy for choroidal
melanoma: V. Twelve-year mortality rates and prognostic factors:
COMS report no. 28. Arch Ophthalmol. 124:1684–1693. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
van Beek JGM, van Rij CM, Baart SJ,
Yavuzyigitoglu S, Bergmann MJ, Paridaens D, Naus NC and Kiliç E:
Fractionated stereotactic radiotherapy for uveal melanoma:
Long-term outcome and control rates. Acta Ophthalmol. 100:511–519.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yazici G, Kiratli H, Ozyigit G, Sari SY,
Cengiz M, Tarlan B, Mocan BO and Zorlu F: Stereotactic radiosurgery
and fractionated stereotactic radiation therapy for the treatment
of uveal melanoma. Int J Radiat Oncol Biol Phys. 98:152–158.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Verma V and Mehta MP: Clinical outcomes of
proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol).
28:e17–e27. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Weber D, Bogner J, Verwey J, Georg D,
Dieckmann K, Escudé L, Caro M, Pötter R, Goitein G, Lomax AJ and
Miralbell R: Proton beam radiotherapy versus fractionated
stereotactic radiotherapy for uveal melanomas: A comparative study.
Int J Radiat Oncol Biol Phys. 63:373–384. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sikuade MJ, Salvi S, Rundle PA, Errington
DG, Kacperek A and Rennie IG: Outcomes of treatment with
stereotactic radiosurgery or proton beam therapy for choroidal
melanoma. Eye (Lond). 29:1194–1198. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Muller K, Naus N, Nowak PJ, Schmitz PI, de
Pan C, van Santen CA, Marijnissen JP, Paridaens DA, Levendag PC and
Luyten GP: Fractionated stereotactic radiotherapy for uveal
melanoma, late clinical results. Radiother Oncol. 102:219–224.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dunavoelgyi R, Zehetmayer M, Gleiss A,
Geitzenauer W, Kircher K, Georg D, Schmidt-Erfurth U, Poetter R and
Dieckmann K: Hypofractionated stereotactic photon radiotherapy of
posteriorly located choroidal melanoma with five fractions at ten
Gy-clinical results after six years of experience. Radiother Oncol.
108:342–347. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Somani S, Sahgal A, Krema H, Heydarian M,
McGowan H, Payne D, Xu W, Michaels H, Laperriere N and Simpson ER:
Stereotactic radiotherapy in the treatment of juxtapapillary
choroidal melanoma: 2-Year follow-up. Can J Ophthalmol. 44:61–65.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Krema H, Heydarian M, Beiki-Ardakani A,
Weisbrod D, Xu W, Simpson ER and Sahgal A: A comparison between
125Iodine brachytherapy and stereotactic radiotherapy in
the management of juxtapapillary choroidal melanoma. Br J
Ophthalmol. 97:327–332. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Krema H, Heydarian M, Beiki-Ardakani A,
Weisbrod D, Xu W, Laperriere NJ and Sahgal A: Dosimetric and late
radiation toxicity comparison between iodine-125 brachytherapy and
stereotactic radiation therapy for juxtapapillary choroidal
melanoma. Int J Radiat Oncol Biol Phys. 86:510–515. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
van Beek JGM, Ramdas WD, Angi M, van Rij
CM, Naus NC, Kacperek A, Errington RD, Damato B, Heimann H and
Kiliç E: Local tumour control and radiation side effects for
fractionated stereotactic photon beam radiotherapy compared to
proton beam radiotherapy in uveal melanoma. Radiother Oncol.
157:219–224. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wijerathne H, Langston JC, Yang Q, Sun S,
Miyamoto C, Kilpatrick LE and Kiani MF: Mechanisms of
radiation-induced endothelium damage: Emerging models and
technologies. Radiother Oncol. 158:21–32. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Silva-Rodríguez P, Fernández-Díaz D, Bande
M, Pardo M, Loidi L and Blanco-Teijeiro MJ: GNAQ and GNA11 genes: A
comprehensive review on oncogenesis, prognosis and therapeutic
opportunities in uveal melanoma. Cancers (Basel).
14(3066)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yu L, Zhou D, Zhang G, Ren Z, Luo X, Liu
P, Plouffe SW, Meng Z, Moroishi T, Li Y, et al: Co-occurrence of
BAP1 and SF3B1 mutations in uveal melanoma induces cellular
senescence. Mol Oncol. 16:607–629. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Decatur CL, Ong E, Garg N, Anbunathan H,
Bowcock AM, Field MG and Harbour JW: Driver mutations in uveal
melanoma: associations with gene expression profile and patient
outcomes. JAMA Ophthalmol. 134:728–733. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mergener S, Siveke JT and Peña-Llopis S:
Monosomy 3 is linked to resistance to MEK inhibitors in uveal
melanoma. Int J Mol Sci. 22(6727)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Khalili JS, Yu X, Wang J, Hayes BC, Davies
MA, Lizee G, Esmaeli B and Woodman SE: Combination small molecule
MEK and PI3K inhibition enhances uveal melanoma cell death in a
mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res.
18:4345–4355. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Leyvraz S, Konietschke F, Peuker C,
Schütte M, Kessler T, Ochsenreither S, Ditzhaus M, Sprünken ED,
Dörpholz G, Lamping M, et al: Biomarker-driven therapies for
metastatic uveal melanoma: A prospective precision oncology
feasibility study. Eur J Cancer. 169:146–155. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Khan S, Lutzky J, Shoushtari AN, Jeter J,
Chiuzan C, Sender N, Blumberg LE, Nesson A, Singh-Kandah SV,
Hernandez S, et al: Adjuvant crizotinib in high-risk uveal melanoma
following definitive therapy. J Clin Oncol. 38 (15
Suppl)(S10075)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Park JJ, Stewart A, Irvine M, Pedersen B,
Ming Z, Carlino MS, Diefenbach RJ and Rizos H: Protein kinase
inhibitor responses in uveal melanoma reflects a diminished
dependency on PKC-MAPK signaling. Cancer Gene Ther. 29:1384–1393.
2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ahmadian SS, Dryden IJ, Naranjo A, Toland
A, Cayrol RA, Born DE, Egbert PS, Brown RA, Mruthyunjaya P and Lin
JH: Preferentially expressed antigen in melanoma
immunohistochemistry labeling in uveal melanomas. Ocul Oncol
Pathol. 8:133–140. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
National Comprehensive Cancer Network
(NCCN) Guidelines Version 1.2023 Melanoma: Uveal. Available online:
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488.
|
|
33
|
Damato B, Kacperek A, Chopra M, Campbell
IR and Errington RD: Proton beam radiotherapy of choroidal
melanoma: The liverpool-clatterbridge experience. Int J Radiat
Oncol Biol Phys. 62:1405–1411. 2005.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hrbacek J, Mishra K, Kacperek A, Dendale
R, Nauraye C, Auger M, Herault J, Daftari IK, Trofimov AV, Shih HA,
et al: Practice patterns analysis of ocular proton therapy centers:
The international optic survey. Int J Radiat Oncol Biol Phys.
95:336–343. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang Z, Nabhan M, Schild SE, Stafford SL,
Petersen IA, Foote RL and Murad MH: Charged particle radiation
therapy for uveal melanoma: A systematic review and meta-analysis.
Int J Radiat Oncol Biol Phys. 86:18–26. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Particle therapy facilities in clinical
operation. Particle Therapy Co-Operative Group (PTCOG). Available
online: https://www.ptcog.site/index.php/facilities-in-operation-public.
|
|
37
|
Otto K: Volumetric modulated arc therapy:
IMRT in a single gantry arc. Med Phys. 35:310–317. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Teoh M, Clark CH, Wood K, Whitaker S and
Nisbet A: Volumetric modulated arc therapy: A review of current
literature and clinical use in practice. Br J Radiol. 84:967–996.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Macchia G, Deodato F, Cilla S, Cammelli S,
Guido A, Ferioli M, Siepe G, Valentini V, Morganti AG and
Ferrandina G: Volumetric modulated arc therapy for treatment of
solid tumors: Current insights. Onco Targets Ther. 10:3755–3772.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jager M, Shields C..Cebulla C,
Abdel-Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort
RN, Jia R, Shields JA and Damato BE: Uveal melanoma. Nat Rev Dis
Primers. 6(24)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Akbaba S, Foerster R, Nicolay NH, Arians
N, Bostel T, Debus J and Hauswald H: Linear accelerator-based
stereotactic fractionated photon radiotherapy as an eye-conserving
treatment for uveal melanoma. Radiat Oncol. 13(140)2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ataides FG, Silva SFBR and Baldin JJCMC:
Radiation-induced optic neuropathy: Literature review.
Neuroophthalmology. 45:172–180. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mishra KK, Daftari IK, Weinberg V, Cole T,
Quivey JM, Castro JR, Phillips TL and Char DH: Risk factors for
neovascular glaucoma after proton beam therapy of uveal melanoma: A
detailed analysis of tumor and dose-volume parameters. Int J Radiat
Oncol Biol Phys. 87:330–336. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pagliara MM, Tagliaferri L, Azario L,
Lenkowicz J, Lanza A, Autorino R, Caputo CG, Gambacorta MA,
Valentini V and Blasi MA: Ruthenium brachytherapy for uveal
melanomas: Factors affecting the development of radiation
complications. Brachytherapy. 17:432–438. 2018.PubMed/NCBI View Article : Google Scholar
|
